Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupSGX:P8A 41 Return-on-Tangible-Asset is -2.45% as of Jun. 2026. GuruFocus rates SGX:P8A with a GF Score™ of 41/100 and a GF Value™ of S$0.14 (Fairly Valued). The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 58.96% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cordlife Group's annualizedNet Income for the quarter that ended in Jun. 2026 was S$-4.20 Mil. Cordlife Group's average total tangible assets for the quarter that ended in Jun. 2026 was S$0.00 Mil. Therefore, Cordlife Group's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -2.45%.
The historical rank and industry rank for Cordlife Group's Return-on-Tangible-Asset or its related term are showing as below:
SGX:P8A'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -9.77 Med: 2.75 Max: 12.5
Current: -6.12
During the past 13 years, Cordlife Group's highest Return-on-Tangible-Asset was 12.50%. The lowest was -9.77%. And the median was 2.75%.
SGX:P8A's Return-on-Tangible-Asset is ranked worse than 58.96% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.755
vs SGX:P8A: -6.12
Cordlife Group (SGX:P8A) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Cordlife Group Return-on-Tangible-Asset Related Terms
Cordlife Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:P8A vs TMO, DHR, NTRA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -2.45% mean?
Cordlife Group (SGX:P8A) has a Return-on-Tangible-Asset of -2.45% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #125 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 59%.
Is Cordlife Group's Return-on-Tangible-Asset too high?
Cordlife Group's current Return-on-Tangible-Asset is -2.45%. Based on the distribution chart, Cordlife Group ranks #125 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cordlife Group has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #125 out of 212 companies for Return-on-Tangible-Asset. This places Cordlife Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cordlife Group and its competitors. Cordlife Group's current Return-on-Tangible-Asset is -2.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (SGX:P8A) is currently considered Fairly Valued. The stock's GF Value™ is S$0.14, compared to a current price of S$0.13 — trading 5.7% below its estimated fair value. The current Return-on-Tangible-Asset is -2.45%. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Cordlife Group (SGX:P8A), the current Return-on-Tangible-Asset is -2.45% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (SGX:P8A) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of S$0.13 is trading 5.7% below its estimated GF Value™ of S$0.14.
GuruFocus considers Cordlife Group to be Fairly Valued.
Key valuation signals for SGX:P8A:
Return-on-Tangible-Asset: -2.45%
GF Value™: S$0.14 vs. price of S$0.13 (5.7% below fair value)
No single metric tells the full story. See the SGX:P8A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score
Get the complete analysis for SGX:P8A
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:P8A has been successfully added to your 
